ClinicalTrials.gg
TerminatedNCT03567616Updated Jun 30, 2021Results posted

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 2 interventional study of Venetoclax and Pomalidomide in Multiple Myeloma, sponsored by AbbVie. Terminated at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Why this study was terminated
Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing venetoclax in Multiple Myeloma — 4 open to participants now, 9 under way, 2 of them phase 3. venetoclax · Multiple Myeloma.

Enrollment
15th of 20
8 · median 42
Started
2018
with 3 others
Phase 2
6 of 20
2 open now
Registered
10th of 20
by date
Lead sponsor
10 of 20
AbbVie

Among the 20 studies testing venetoclax in Multiple Myeloma, this one is the 15th largest by enrollment, is one of 4 that started in 2018, is one of 6 in phase 2, and was the 10th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

4 of the 20 studies testing venetoclax in Multiple Myeloma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing venetoclax in Multiple Myeloma, or all of them as a file.
02

Study summary

This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM) who received at least 1 prior line of therapy with documented evidence of progression during or after the participant's last treatment regimen. The study was designed to consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the participants were to be divided into 2 cohorts, participants positive for t(11;14) translocation and participants negative for t(11;14) translocation.

Read the detailed description

Following communication of the results of the primary progression-free survival (PFS) analysis from the Phase 3 BELLINI study (Study M14-031; NCT02755597), the company-sponsored MM studies were placed on partial clinical hold (PCH) in March 2019 by the United States (US) Food and Drug Administration and enrollment was halted. The sponsor did not pursue release of the PCH for this study; therefore, enrollment was not re-opened. In accordance with the terms of the PCH, participants who were deriving clinical benefit were allowed to continue to receive treatment. One participant was still active in Part 1 of the study when the sponsor decided not to pursue release of the PCH (in January 2020) and, therefore, continued to receive treatment and have regular assessments until disease progression. The study was discontinued when the last participant completed study treatment. No participants were enrolled in Part 2 of the study.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Cancer
  • Multiple Myeloma (MM)
  • Relapsed or Refractory (R/R)
  • Venetoclax
  • Pomalidomide
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen
  • as described in the protocol
  • Received at least 1 as described in the protocol
  • Must meet prior antimyeloma treatment parameters, as described in the protocol, and includes:
  • Received at least 2 consecutive cycles of lenalidomide or a lenalidomide-containing regimen
  • Refractory to lenalidomide
  • Exposed to a proteasome inhibitor (PI) alone or in combination with another agent
  • Had a response of partial response (PR) or better to prior therapy based on the investigator's determination of response as defined by International Myeloma Working Group (IMWG) criteria
  • Has t(11;14) status as described in the protocol and meets the following criteria:
  • For Part 1: MM participants independent of cytogenetic profile
  • For Part 2, Arm A: participant must be t(11;14) positive
  • For Part 2, Arm B: participant must be t(11;14) negative
  • An (ECOG) performance status ≤ 2
  • Adequate kidney, liver and hematologic laboratory values

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with venetoclax or other BCL-2 inhibitors, or previous treatment with pomalidomide
  • Known sensitivity to any IMiDs
  • Allogenic or syngeneic stem cell transplant within 6 months before the first dose of study drug or active ongoing
  • stem cell transplant within 12 weeks before the first dose of study drug
  • Known meningeal involvement of MM
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Escalation

    Venetoclax (400 mg oral \[PO\], once daily \[QD\]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly \[qw\]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol

    Drug: Venetoclax · Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    Part 2: Dose Expansion, t(11;14) positive

    Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])

    Drug: Venetoclax · Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    Part 2: Dose Expansion, t(11;14) negative

    Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral \[PO\], once daily \[QD\]) and dexamethasone (40 mg once weekly \[qw\])

    Drug: Venetoclax · Drug: Pomalidomide · Drug: Dexamethasone

Interventions

  • Tablet; oral

    Also known as: ABT-199, GDC-0199, Venclexta

  • Capsule; oral

    Also known as: Pomalyst

  • Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to 70 weeks)

  2. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants experiencing a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using the International Myeloma Working Group (IMWG) 2016 criteria for disease response and progression. CR= negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow; sCR= CR + normal serum free light chain (FLC) ratio and absence of clonal cells in bone marrow; VGPR= serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level + urine M-protein level \< 100 mg per 24 hours; PR= ≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours.

    Time frame: Approximately 15 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the number of days from the date of first dose of any study drug to the date of disease progression or death, whichever occurs first. All disease progression was to be included regardless of whether the event occurred during or after the participant was taking any study drug.

    Time frame: Approximately 20 months

  2. Duration of Response (DOR)

    DOR for a given participant is defined as the number of days from the date of that participant's first documented response (Partial Response \[PR\] or better) to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant with a documented response did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.

    Time frame: Approximately 15 months

  3. Time-to-progression (TTP)

    TTP for a given participant is defined as the number of days from the date of first dose to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.

    Time frame: Approximately 15 months

07

Results

Posted Jun 30, 2021

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started8
Completed0
Not completed8
Withdrew: Disease progression4
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1
Withdrew: Death1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

Time frame:
From first dose of study drug until 30 days following last dose of study drug (up to 70 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsParticipants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) Translocation
Any TEAE35
TESAE32
PrimaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants experiencing a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) using the International Myeloma Working Group (IMWG) 2016 criteria for disease response and progression. CR= negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow; sCR= CR + normal serum free light chain (FLC) ratio and absence of clonal cells in bone marrow; VGPR= serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein level + urine M-protein level \< 100 mg per 24 hours; PR= ≥ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours.

Time frame:
Approximately 15 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsParticipants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) TranslocationAll Participants
Overall Response Rate (ORR)66.7 (9.4 to 99.2)60.0 (14.7 to 94.7)62.5 (24.5 to 91.5)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the number of days from the date of first dose of any study drug to the date of disease progression or death, whichever occurs first. All disease progression was to be included regardless of whether the event occurred during or after the participant was taking any study drug.

Time frame:
Approximately 20 months
Reported as:
Median · days
Progression-Free Survival (PFS)
daysParticipants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) TranslocationAll Participants
Progression-Free Survival (PFS)220.0 (11.0 to NA)NA (57.0 to NA)320.0 (11.0 to NA)
SecondaryDuration of Response (DOR)

DOR for a given participant is defined as the number of days from the date of that participant's first documented response (Partial Response \[PR\] or better) to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant with a documented response did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.

Time frame:
Approximately 15 months
Reported as:
Median · days
Duration of Response (DOR)
daysParticipants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) TranslocationAll Participants
Duration of Response (DOR)393.0 (NA to NA)NA (NA to NA)393.0 (NA to NA)
SecondaryTime-to-progression (TTP)

TTP for a given participant is defined as the number of days from the date of first dose to the date of first documented disease progression (PD) or death due to multiple myeloma (MM), whichever occurs first. If the participant did not have an event of PD and the participant had not died due to MM, the participant's data was to be censored.

Time frame:
Approximately 15 months
Reported as:
Median · days
Time-to-progression (TTP)
daysParticipants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) TranslocationAll Participants
Time-to-progression (TTP)420.0 (NA to NA)NA (57.0 to NA)420.0 (57.0 to NA)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last study drug administration, up to 70 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Positive for t(11;14) Translocation2/3 (66.7%)3/3 (100%)3/3 (100%)
Participants Negative for t(11;14) Translocation0/5 (0%)2/5 (40%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventParticipants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) Translocation
CARDIO-RESPIRATORY ARRESTCardiac disorders1/30/5
PNEUMONIA STREPTOCOCCALInfections and infestations1/30/5
BLOOD LACTATE DEHYDROGENASE INCREASEDInvestigations1/30/5
PANCREATIC NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/5
CEREBRAL INFARCTIONNervous system disorders1/30/5
CEREBROVASCULAR ACCIDENTNervous system disorders1/30/5
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders1/30/5
ATRIAL FIBRILLATIONCardiac disorders0/31/5
PNEUMOCOCCAL INFECTIONInfections and infestations0/31/5
PNEUMONIAInfections and infestations0/31/5
Most frequent other events
Showing 10 of 71
Most frequent other events
EventParticipants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) Translocation
NEUTROPENIABlood and lymphatic system disorders2/34/5
FATIGUEGeneral disorders2/32/5
DYSPNOEARespiratory, thoracic and mediastinal disorders2/31/5
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders2/30/5
ANAEMIABlood and lymphatic system disorders1/33/5
HYPERGLYCAEMIAMetabolism and nutrition disorders0/33/5
HYPOKALAEMIAMetabolism and nutrition disorders1/33/5
LEUKOPENIABlood and lymphatic system disorders1/32/5
LYMPHOPENIABlood and lymphatic system disorders0/32/5
THROMBOCYTOPENIABlood and lymphatic system disorders1/32/5

Baseline characteristics

Full Analysis Set: participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Participants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) TranslocationTotal
Median68.0 (67 to 74)66.0 (60 to 77)67.5 (60 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Participants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) TranslocationTotal
Female145
Male213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Positive for t(11;14) TranslocationParticipants Negative for t(11;14) TranslocationTotal
White347
Black/African American011
Asian000
Other000
08

Study locations

11 sites
  • John B. Amos Cancer Center - C /ID# 202055
    Columbus, Georgia 31904, United States
  • University of Kansas Cancer Center /ID# 201292
    Fairway, Kansas 66205-2528, United States
  • Washington University-School of Medicine /ID# 201287
    Saint Louis, Missouri 63110, United States
  • Duke University Hospital /ID# 200805
    Durham, North Carolina 27710, United States
  • Ohio State Cancer Center /ID# 202443
    Columbus, Ohio 43210, United States
  • Hospital Universitario Germans Trias i Pujol /ID# 200959
    Badalona, Barcelona 08916, Spain
  • Hospital Universitario Vall d'Hebron /ID# 200967
    Barcelona, 08035, Spain
  • Hospital Clinico Universitario de Salamanca /ID# 200958
    Salamanca, 37007, Spain
  • Leicester Royal Infirmary /ID# 202238
    Leicester, England LE1 5WW, United Kingdom
  • Norfolk and Norwich Univ Hosp /ID# 202240
    Norwich, Norfolk NR4 7UY, United Kingdom
  • Univ Hospitals Birmingham NHS Foundation trust /ID# 203188
    Birmingham, B15 2TG, United Kingdom
09

References and documents

Publications

  • Gasparetto C, Bowles KM, Abdallah AO, Morris L, Mander G, Coppola S, Wang J, Ross JA, Bueno OF, Arriola E, Mateos MV. A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):775-784. doi: 10.1016/j.clml.2021.07.029. Epub 2021 Aug 1. PubMed 34551886 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jun 2020, 20 months.

Results were first posted in Jun 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2018
First posted
Jun 26, 2018
StartActual
Oct 18, 2018
Primary completionActual
Jun 18, 2020
CompletionActual
Jun 18, 2020
Results first posted
Jun 30, 2021
Last update
Jun 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03567616
Lead sponsor
AbbVie
Collaborators
Celgene
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Oct 18, 2018
Primary completion
Jun 18, 2020
Completion
Jun 18, 2020
Results posted
Jun 30, 2021
Last update
Jun 30, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Pomalidomide · Dexamethasone

Start the discussion